April 24, 2024 Second notice of the Ordinary and Extraordinary Shareholders’ Meeting on May 6, 2024 and appointment of an ad hoc agent
March 20, 2024 Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology